Skip to main content

Table 3 Association between the ITIH5 methylation status and cytogenetic findings in the patient cohort

From: Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia

Cytogenetic risk

ITIH5 hypermethylation (%)

Total number of patients (n = 104)

14.4% (15/104)

Favorable risk (n = 16)

18.8% (3/16)

 inv(16) (n = 11)

27.3% (3/11)

 t(8;21) (n = 5)

0%

Intermediate risk (n = 60)

11.7% (7/60)

Unfavorable risk (n = 14)

7.1% (1/14)

Karyotype n.a. (n = 14)

28.6% (4/14)

  1. n.a. not available